Anavex Life Sciences Corp. (0HFR.L)
USD 8.21
(3.62%)
USD 8.21
(3.62%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 12.53 Million USD | 22.72% |
| 2022 | 10.21 Million USD | -5.42% |
| 2021 | 10.79 Million USD | 47.81% |
| 2020 | 7.3 Million USD | 44.96% |
| 2019 | 5.03 Million USD | 29.73% |
| 2018 | 3.88 Million USD | 8.38% |
| 2017 | 3.58 Million USD | 12.34% |
| 2016 | 3.19 Million USD | 19.9% |
| 2015 | 2.66 Million USD | -62.84% |
| 2014 | 7.16 Million USD | 150.67% |
| 2013 | 2.85 Million USD | -1.1% |
| 2012 | 2.88 Million USD | 114.67% |
| 2011 | 1.34 Million USD | -59.11% |
| 2010 | 3.29 Million USD | -22.89% |
| 2009 | 4.26 Million USD | 85.55% |
| 2008 | 2.29 Million USD | 397.13% |
| 2007 | 462.52 Thousand USD | 1551.54% |
| 2006 | 28 Thousand USD | 3.74% |
| 2005 | 26.99 Thousand USD | 977.72% |
| 2004 | 2505.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 11.75 Million USD | 22.98% |
| 2024 Q1 | 12.49 Million USD | -0.31% |
| 2024 Q2 | 9.55 Million USD | -23.51% |
| 2023 Q3 | 11.05 Million USD | -21.15% |
| 2023 Q4 | 12.53 Million USD | 13.38% |
| 2023 FY | 12.53 Million USD | 22.72% |
| 2023 Q1 | 13.24 Million USD | 29.71% |
| 2023 Q2 | 14.02 Million USD | 5.84% |
| 2022 Q3 | 9.48 Million USD | 17.51% |
| 2022 FY | 10.21 Million USD | -5.42% |
| 2022 Q4 | 10.21 Million USD | 7.69% |
| 2022 Q1 | 10.52 Million USD | -2.5% |
| 2022 Q2 | 8.07 Million USD | -23.34% |
| 2021 Q1 | 8.03 Million USD | 9.96% |
| 2021 FY | 10.79 Million USD | 47.81% |
| 2021 Q2 | 7.76 Million USD | -3.36% |
| 2021 Q3 | 9.27 Million USD | 19.45% |
| 2021 Q4 | 10.79 Million USD | 16.44% |
| 2020 Q1 | 5.46 Million USD | 8.42% |
| 2020 FY | 7.3 Million USD | 44.96% |
| 2020 Q2 | 6.22 Million USD | 14.0% |
| 2020 Q3 | 6.94 Million USD | 11.57% |
| 2020 Q4 | 7.3 Million USD | 5.13% |
| 2019 Q2 | 6.37 Million USD | 30.66% |
| 2019 Q1 | 4.87 Million USD | 25.52% |
| 2019 Q4 | 5.03 Million USD | 16.21% |
| 2019 FY | 5.03 Million USD | 29.73% |
| 2019 Q3 | 4.33 Million USD | -31.93% |
| 2018 Q4 | 3.88 Million USD | 21.05% |
| 2018 FY | 3.88 Million USD | 8.38% |
| 2018 Q3 | 3.2 Million USD | -6.08% |
| 2018 Q1 | 2.79 Million USD | -21.92% |
| 2018 Q2 | 3.41 Million USD | 22.09% |
| 2017 Q3 | 1.45 Million USD | -31.38% |
| 2017 Q4 | 3.58 Million USD | 146.42% |
| 2017 Q1 | 2.19 Million USD | -31.2% |
| 2017 FY | 3.58 Million USD | 12.34% |
| 2017 Q2 | 2.11 Million USD | -3.42% |
| 2016 FY | 3.19 Million USD | 19.9% |
| 2016 Q1 | 2.53 Million USD | -4.82% |
| 2016 Q2 | 2.43 Million USD | -3.97% |
| 2016 Q4 | 3.19 Million USD | 46.83% |
| 2016 Q3 | 2.17 Million USD | -10.66% |
| 2015 Q1 | 6.57 Million USD | -8.15% |
| 2015 Q3 | 1.01 Million USD | -38.72% |
| 2015 FY | 2.66 Million USD | -62.84% |
| 2015 Q2 | 1.66 Million USD | -74.73% |
| 2015 Q4 | 2.66 Million USD | 161.27% |
| 2014 Q1 | 1.82 Million USD | -36.25% |
| 2014 Q2 | 1.88 Million USD | 3.47% |
| 2014 Q3 | 1.9 Million USD | 1.11% |
| 2014 Q4 | 7.16 Million USD | 275.85% |
| 2014 FY | 7.16 Million USD | 150.67% |
| 2013 Q2 | 3.43 Million USD | 0.78% |
| 2013 Q3 | 3.55 Million USD | 3.54% |
| 2013 FY | 2.85 Million USD | -1.1% |
| 2013 Q1 | 3.4 Million USD | 18.01% |
| 2013 Q4 | 2.85 Million USD | -19.69% |
| 2012 Q2 | 3.11 Million USD | 21.57% |
| 2012 Q1 | 2.56 Million USD | 90.71% |
| 2012 FY | 2.88 Million USD | 114.67% |
| 2012 Q4 | 2.88 Million USD | 30.11% |
| 2012 Q3 | 2.21 Million USD | -28.84% |
| 2011 FY | 1.34 Million USD | -59.11% |
| 2011 Q4 | 1.34 Million USD | -40.27% |
| 2011 Q1 | 582.93 Thousand USD | -82.28% |
| 2011 Q3 | 2.25 Million USD | 74.14% |
| 2011 Q2 | 1.29 Million USD | 121.91% |
| 2010 FY | 3.29 Million USD | -22.89% |
| 2010 Q2 | 5.84 Million USD | 28.37% |
| 2010 Q3 | 8.84 Million USD | 51.28% |
| 2010 Q1 | 4.55 Million USD | 6.77% |
| 2010 Q4 | 3.29 Million USD | -62.81% |
| 2009 Q1 | 2.75 Million USD | 19.96% |
| 2009 Q4 | 4.26 Million USD | 21.76% |
| 2009 Q3 | 3.5 Million USD | 7.06% |
| 2009 Q2 | 3.27 Million USD | 18.65% |
| 2009 FY | 4.26 Million USD | 85.55% |
| 2008 Q3 | 1.79 Million USD | 61.67% |
| 2008 Q1 | 498.72 Thousand USD | 7.83% |
| 2008 Q4 | 2.29 Million USD | 28.4% |
| 2008 FY | 2.29 Million USD | 397.13% |
| 2008 Q2 | 1.1 Million USD | 122.11% |
| 2007 Q4 | 462.52 Thousand USD | 2.36% |
| 2007 Q2 | 211.93 Thousand USD | 555.69% |
| 2007 Q1 | 32.32 Thousand USD | 15.41% |
| 2007 Q3 | 451.87 Thousand USD | 113.22% |
| 2007 FY | 462.52 Thousand USD | 1551.54% |
| 2006 Q3 | 29.63 Thousand USD | -21.74% |
| 2006 Q2 | 37.87 Thousand USD | 14.03% |
| 2006 Q4 | 28 Thousand USD | -5.5% |
| 2006 FY | 28 Thousand USD | 3.74% |
| 2006 Q1 | 33.21 Thousand USD | 23.02% |
| 2005 Q4 | 26.99 Thousand USD | 0.0% |
| 2005 FY | 26.99 Thousand USD | 977.72% |
| 2004 FY | 2505.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 97.991% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 90.06% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 97.971% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 95.265% |
| bluebird bio, Inc. | 424.62 Million USD | 97.048% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 81.771% |
| Imunon, Inc. | 8.53 Million USD | -46.933% |
| Editas Medicine, Inc. | 150.05 Million USD | 91.647% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.939% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 99.642% |
| Myriad Genetics, Inc. | 312.9 Million USD | 95.994% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 98.77% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 97.429% |
| Verastem, Inc. | 71.18 Million USD | 82.392% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.982% |
| Waters Corporation | 3.47 Billion USD | 99.639% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.976% |
| Biogen Inc. | 12.04 Billion USD | 99.896% |
| Nektar Therapeutics | 267.04 Million USD | 95.306% |
| Perrigo Company plc | 6.04 Billion USD | 99.793% |
| Dynavax Technologies Corporation | 375.02 Million USD | 96.658% |
| Illumina, Inc. | 4.36 Billion USD | 99.713% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | 64.369% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 93.597% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 95.113% |
| Unity Biotechnology, Inc. | 37.29 Million USD | 66.39% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 99.337% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 84.795% |
| Evolus, Inc. | 209.68 Million USD | 94.023% |
| Adicet Bio, Inc. | 37.12 Million USD | 66.234% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 68.841% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.824% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 98.103% |
| FibroGen, Inc. | 585.72 Million USD | 97.86% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 99.745% |
| OPKO Health, Inc. | 622.47 Million USD | 97.986% |
| Homology Medicines, Inc. | 118.53 Million USD | 89.426% |
| Geron Corporation | 146.12 Million USD | 91.423% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.691% |
| Exelixis, Inc. | 678.44 Million USD | 98.153% |
| Viking Therapeutics, Inc. | 20.07 Million USD | 37.552% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 95.003% |
| Zoetis Inc. | 9.29 Billion USD | 99.865% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 96.845% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 74.512% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.757% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 74.127% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 99.519% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 99.479% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 89.083% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 99.24% |
| Blueprint Medicines Corporation | 918.64 Million USD | 98.636% |
| Insmed Incorporated | 1.66 Billion USD | 99.246% |
| TG Therapeutics, Inc. | 169.08 Million USD | 92.587% |
| Incyte Corporation | 1.59 Billion USD | 99.213% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 98.943% |